Heather Jim, PhD, program co-leader, Health Outcomes and Behavior Program, Moffitt Cancer Center, discusses a real-world analysis, examining the quality of life outcomes seen with axicabtagene ciloleucel (axi-cel; Yescarta) in patients with relapsed/refractory large B-cell lymphoma (LBCL).

Investigators assessed 53 patients’ quality of life prior to treatment with CAR T-cell therapy, followed by additional assessments following treatment with CAR T-cell therapy at 14, 30, 60, 90, 180, and 360 days, Jim explains. It was found that most patients quality of life improved, despite a dip in quality of life at baseline, Jim adds.

Patients’ quality of life was determined by physical functioning, role functioning, social functioning, and global quality of life, Jim continues. Notably, by 1 year, the same patients were reporting a quality of life comparable to patients who never had cancer, Jim concludes.

Videos

Heather Jim, PhD, discusses a real-world analysis, examining the quality of life outcomes seen with axicabtagene ciloleucel in patients with relapsed/refractory large B-cell lymphoma.

Dr. Jim on Real-World Quality of Life Outcomes With Axi-Cel in R/R LBCL

Heather S. Jim, PhD, associate member in the Health Outcomes and Behavioral Department, Moffitt Cancer Center, discusses the effects of testosterone-lowering drugs used as treatment for patients with prostate cancer.

Androgen-deprivation therapy is associated with several side effects that include depression, cognitive impairment, fatigue, loss of muscle mass, and inflammation, as well as cardiovascular disease and cardiovascular mortality, Jim explains.

Regarding depression, research out of Moffitt Cancer Center suggests that 40% of patients experience clinically significant depressive symptoms after approximately 6 months of ADT. Jim adds that it is important to treat depression not only to help patients feel better, but because depression is associated with increased mortality in patients with prostate cancer.

Heather S. Jim, PhD, associate member in the Health Outcomes and Behavioral Department, Moffitt Cancer Center, discusses the effects of testosterone-lowering drugs used as a treatment for patients with prostate cancer.

Heather S. Jim, PhD

Articles

Dr. Jim on Real-World Quality of Life Outcomes With Axi-Cel in R/R LBCL

Effects of Testosterone-Lowering Drugs in Patients With Prostate Cancer